疏风解毒胶囊对慢性阻塞性肺疾病急性加重期的疗效评价

发布时间：2018-05-18 14:57

本文选题：疏风解毒胶囊 + 慢性阻塞性肺疾病　；参考：《中华中医药杂志》2017年01期

【摘要】：目的:评价疏风解毒胶囊对慢性阻塞性肺疾病(COPD)急性加重期的临床疗效和安全性。方法:COPD急性加重期患者40例按完全随机分组法分为:试验组20例,对照组20例。试验组疏风解毒胶囊口服加常规治疗,对照组常规治疗,疗程1周。比较两组患者临床症状缓解情况、住院天数、血常规及超敏C-反应蛋白(hsCRP),并取住院时、出院时患者血清行呼吸道合胞病毒Ig M、甲型流感病毒抗原检测。结果:治疗后,试验组临床显效率高于对照组(P0.01);试验组住院天数明显少于对照组(P0.01)。治疗前两组患者白细胞计数(WBC)、中性粒细胞百分比(N%)、hs-CRP、血清呼吸道合胞病毒Ig M、甲型流感病毒抗原等临床指标比较差异无统计学意义。治疗后两组患者WBC、N%、hs-CRP、甲型流感病毒抗原等临床指标较治疗前均显著降低(P0.01),血清呼吸道合胞病毒Ig M比较,差异无统计学意义,其中,试验组患者血清WBC、N%、hs-CRP、甲型流感病毒抗原等临床指标好于对照组(P0.01)。试验组出现轻微恶心1例。结论:疏风解毒胶囊对COPD急性加重期患者疗效确切安全,可减少住院时间。
[Abstract]:Objective: to evaluate the clinical efficacy and safety of Shufeng jiedu capsule in acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods 40 patients with acute exacerbation of COPD were randomly divided into trial group (n = 20) and control group (n = 20). Shufeng jiedu capsule was administered orally in the test group and conventional therapy was performed in the control group for 1 week. The clinical symptom relief, hospitalization days, blood routine examination and hypersensitive C-reactive protein hsCRPN were compared between the two groups. The serum samples of respiratory syncytial virus (RSV) and influenza A virus antigen were detected at the time of discharge. Results: after treatment, the clinical effective rate of the trial group was higher than that of the control group (P 0.01), and the days of hospitalization in the test group was significantly less than that in the control group (P 0.01). There was no significant difference in WBC count, neutrophil percentage, serum respiratory syncytial virus IgG M and influenza A virus antigen between the two groups before treatment. After the treatment, the clinical indexes such as WBCN, Hs-CRPand influenza A virus antigen in the two groups were significantly lower than those before treatment. There was no significant difference between the two groups in serum respiratory syncytial virus IgG M, among which, there was no significant difference between the two groups. The clinical indexes such as serum WBCN and influenza A virus antigen in the test group were better than those in the control group (P 0.01). There was 1 case of slight nausea in the trial group. Conclusion: Shufeng jiedu capsule is safe and effective in acute exacerbation of COPD.
【作者单位】：安徽医科大学第二附属医院呼吸内科;
【分类号】：R563.9

【相似文献】